Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan
Experimental Dermatology · 2024
DOI: 10.1111/exd.15067 ↗At a glance
Journal article in Experimental Dermatology, 2024. Written by Yayoi Tada and 9 co-authors. Institution: Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan. Major MEDLINE topics: Psoriasis, Antibodies, Monoclonal, Humanized. Cited 7 times so far (Crossref); 18 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: AbbVie Inc, AbbVie.
Abstract (original language)
Patients receiving interleukin (IL)‐inhibiting biologics for moderate‐to‐severe psoriasis (PsO) may be treated with escalated doses to optimize outcomes. This study evaluated escalation prevalence in a Japanese claims analysis of patients with PsO diagnosis preceding IL‐inhibiting biologic treatment and ≥1 post‐induction maintenance claim (index date) with sufficient data availability from January 2014 to May 2022. Patients with non‐persistence were excluded. Expected daily dose (EDD) was calculated as the recommended maintenance dose divided by the treatment interval. Dose escalation was defined as ≥2 claims showing a ≥20% increase in the observed average daily dose (ADD) over the EDD (with sensitivities requiring ≥1 claim and ≥30%). Significant differences were tested using multivariable regressions. The study included 982 unique patients treated with brodalumab (BRO; n = 104), guselkumab (GUS; n = 207), ixekizumab (IXE; n = 159), risankizumab (RIS; n = 135), secukinumab (SEC; n = 215) and ustekinumab (UST; n = 196). Within 12 months, dose escalation was observed for all IL‐inhibiting biologics other than GUS and RIS: 44.4% for UST, 37.2% for IXE, 3.4% for SEC and 1.4% for BRO. In multivariable‐adjusted analyses, odds of dose escalation were significantly lower for all products relative to UST. In sensitivities, escalation was observed for all products except RIS.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
- AbbVie Inc., North Chicago, Illinois, USA.
- AbbVie GK, Tokyo, Japan.
- Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany.
- Medicus Economics, LLC, Milton, Massachusetts, USA.
- Department of Dermatology, IIB SANTPAU, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
ORCID profiles: Yayoi Tada, Ahmed M Soliman, Kanako Ishii, Shinichi Imafuku
Funding
- AbbVie Inc
- AbbVie
Cite
APA
Tada, Y., Soliman, A. M., Ishii, K., Sakuma, R., Pinter, A., Davis, M., Nunag, D., Buessing, M., Puig, L., & Imafuku, S. (2024). Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan. Experimental Dermatology. https://doi.org/10.1111/exd.15067
Vancouver
Tada Y, Soliman AM, Ishii K, Sakuma R, Pinter A, Davis M, et al. Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan. Experimental Dermatology. 2024. doi:10.1111/exd.15067
BibTeX
@article{Tada2024,
author = {Tada, Yayoi and Soliman, Ahmed M and Ishii, Kanako and Sakuma, Ryuta and Pinter, Andreas and Davis, Matthew and Nunag, Dominic and Buessing, Marric and Puig, Luis and Imafuku, Shinichi},
title = {Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan},
journal = {Experimental Dermatology},
year = {2024},
doi = {10.1111/exd.15067}
}
EUVIMED